Roth Keeps Ligand (LGND) at 'Buy' Following New Captisol-Based Tech Launch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Apple sues OpenAI, two former employees for trade secrets theft
Ligand Pharma (LGND) Reports Expanded License Agreement with CURx Pharma
September 9, 2014 8:37 AM EDTLigand Pharma (Nasdaq: LGND) has expanded its global license agreement with CURx Pharmaceuticals, Inc. to also include the development and commercialization of Ligands Captisol-enabled Lamotrigine program. Under the terms of the expanded license, Ligand will be eligible to receive $22 million in potential milestone payments,... More
